SCHEMBL6942014

SCHEMBL6942014

CCCCN1CCC(=NO)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.44
GLB1 P16278 1/20 0.38
SIGMAR1 Q99720 5/20 0.37
GNAI3 P08754 1/20 0.37
GNAO1 P09471 1/20 0.37
GNAI1 P63096 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36
EBP Q15125 1/20 0.36
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108441 1.00 CHRNA7 (0.44) CHRNA7GLB1SIGMAR1GNAI3GNAO1
Methylamine SCHEMBL7228187 0.96 CHRNA7 (0.41) CHRNA7GLB1SIGMAR1GNAI3GNAO1
Dimethylamine SCHEMBL8115201 0.94 CHRNA7 (0.40) CHRNA7GLB1SIGMAR1GNAI3GNAO1
Dimethylamine SCHEMBL6950205 0.94 CHRNA7 (0.40) CHRNA7GLB1SIGMAR1GNAI3GNAO1
Diethylamine SCHEMBL6941485 0.91 CHRNA7 (0.38) CHRNA7GLB1SIGMAR1GNAI3GNAO1
SCHEMBL8099579 0.90 CHRNA7 (0.37) CHRNA7GLB1SIGMAR1GNAI3GNAO1
SCHEMBL6939508 0.90 CHRNA7 (0.37) CHRNA7GLB1SIGMAR1GNAI3GNAO1
SCHEMBL6941816 0.90 CHRNA7 (0.37) CHRNA7GNAI3GNAO1GNAI1OPRM1
Dimethylamine SCHEMBL6941904 0.89 GNAI3 (0.41) CHRNA7GNAI3GNAO1GNAI1S1PR1
SCHEMBL6948620 0.89 CYP2D6 (0.42) CHRNA7GLB1SIGMAR1CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed
EP-1056744-A1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043675-A1 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 CHRNA7 3390/4885GLB1 3514/4885SIGMAR1 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.